- Home
- IPEX vs CDXS Comparison
IPEX vs CDXS Comparison
Compare IPEX & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPEX | CDXS |
|---|---|---|
| Founded | 2024 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.4M | 141.8M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | IPEX | CDXS |
|---|---|---|
| Price | $10.36 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | $41.16 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $10.25 | $1.05 |
| 52 Week High | $10.39 | $3.87 |
Technical Indicators
Market Signals| Indicator | IPEX | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 30.08 |
| Support Level | N/A | N/A |
| Resistance Level | $10.35 | $2.55 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 44.44 | 4.29 |
Price Performance
Historical ComparisonAbout IPEX Inflection Point Acquisition Corp. V Class A Ordinary Shares
Inflection Point Acquisition Corp V is a blank check company.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.